Share on StockTwits

Research analysts at BMO Capital Markets decreased their price target on shares of Masimo Corp. (NASDAQ:MASI) from $26.00 to $24.00 in a report released on Friday. BMO Capital Markets’ price objective would suggest a potential downside of 0.95% from the stock’s previous close.

Shares of Masimo Corp. (NASDAQ:MASI) traded down 10.32% on Friday, hitting $21.73. The stock had a trading volume of 2,018,073 shares. Masimo Corp. has a one year low of $19.30 and a one year high of $32.20. The stock has a 50-day moving average of $24.01 and a 200-day moving average of $25.79. The company has a market cap of $1.233 billion and a price-to-earnings ratio of 21.42.

Masimo Corp. (NASDAQ:MASI) last released its earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.29 by $0.05. The company had revenue of $140.92 million for the quarter, compared to the consensus estimate of $145.76 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The company’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Masimo Corp. will post $1.28 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on MASI. Analysts at Roth Capital cut their price target on shares of Masimo Corp. from $32.00 to $28.00 in a research note on Friday. Separately, analysts at Piper Jaffray downgraded shares of Masimo Corp. from an “overweight” rating to a “neutral” rating in a research note on Friday. Finally, analysts at BTIG Research initiated coverage on shares of Masimo Corp. in a research note on Tuesday, July 8th. They set a “buy” rating and a $32.00 price target on the stock. Three analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $27.80.

Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.